Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson's disease patients.

Journal of neurology - 1 Mar 2022

Leocadi Michela, Canu Elisa, Donzuso Giulia, Stojkovic Tanja, Basaia Silvia, Kresojević Nikola, Stankovic Iva, Sarasso Elisabetta, Piramide Noemi, Tomic Aleksandra, Markovic Vladana, Petrovic Igor, Stefanova Elka, Kostic Vladimir S, Filippi Massimo, Agosta Federica

Abstract excerpt

OBJECTIVE: To study the longitudinal disease course of Parkinson's disease (PD) patients with glucocerebrosidase (GBA) mutation (GBA-positive) compared to PD non-carriers (GBA-negative) along a 5-year follow-up, evaluating changes in clinical and cognitive outcomes, cortical thickness, and gray-matter (GM) volumes. METHODS: Ten GBA-positive and 20 GBA-negative PD patients underwent clinical, neuropsychological,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cognition
Share to Cognitive Dysfunction

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucosylceramidase

Share to Gray Matter

Share to Mutation

Share to Parkinson Disease

Source

Identifiers

PMID: 34297177
DOI: 10.1007/s00415-021-10713-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal clinical, cognitive, and neuroanatomical changes over 5 years in GBA-positive Parkinson's disease patients.PMID 34297177Read ↗

Imaging and genetics in Parkinson's disease: assessment of the GBA1 mutation.Semantic proximity Read ↗

Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives.Semantic proximity Read ↗

Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations.Semantic proximity Read ↗

Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses.Semantic proximity Read ↗

Understanding the pattern of cognitive decline in GBA1-related Parkinson’s Disease: a longitudinal multi-cohort studySemantic proximity Read ↗

GBA-Associated Parkinson's Disease and Other Synucleinopathies.Semantic proximity Read ↗

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutationSemantic proximity Read ↗

Transcriptomic signatures associated with regional cortical thickness changes in Parkinson’s diseaseSemantic proximity Read ↗

Large-scale proteomics analysis of five brain regions from Parkinson’s disease patients with a GBA1 mutationSemantic proximity Read ↗

Evolution of prodromal parkinsonian features in a cohort ofGBAmutation-positive individuals: a 6-year longitudinal studySemantic proximity Read ↗

Convergent imaging and genetic signatures of gray matter atrophy in Parkinson's disease.Semantic proximity Read ↗

Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.